Michael Mullan Alzheimers Research

 

The Roskamp Institute is devoted to understanding causes of and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. Based in Sarasota, Florida, the Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease.

Headed by Dr. Michael Mullan, the institute employs experienced and interdisciplinary scientists and technicians and houses state-of-the-art research labs and equipment to conduct scientific research. The quality of research performed at the institute reflects its motto: “Better science. Real discovery.”

 

Michael Mullan is a biomedical researcher of the β-amyloid protein and its relation to Alzheimer’s disease. Mullan’s Alzheimer research is well known among Biomedical Community. Dr. Mullan Alzheimer research work resulted in identifying the most widely known Swiss Mutation that is present in familial form. Transgenic Animal for Alzheimer Disease uses Swiss Mutation.

Dr. Mullan is currently the director[1] of the Roskamp Institute in Sarasota, Florida. Under Dr. Mullan’s guidelines the institute is carrying out cutting edge research in Alzheimer’s, Traumatic Brain Research, Gulf War Illness and other neuropsychiatric disorder.

 

Please visit websites to learn about Dr. Mullan Alzheimer’s Research Website:

 

 

Recent Posts

Amino Acids Improve Sleep in Mice with Traumatic Brain Injury

Amino Acids Improve Sleep in Mice with Traumatic Brain Injury 

A study by Oregon Health and Science University, published in Science Translational Medicine, discovered a way to fix sleep disturbances in mice suffering from traumatic brain injury.  These results are important, because people commonly experience long-term and severe sleep and wakefulness issues after suffering concussions, a mild form of traumatic brain injury. The research hinged on feeding mice branched chain amino acids, something humans naturally produce from food.  Dr. Miranda Lim, first author of the study, hopes that further studies will uphold the results found, and a dietary supplement prescribed as a viable therapy for concussions could be developed.

Nearly two million people in the US suffer traumatic brain injury every year, and nearly 72% have sleep disturbances.  Sleep problems are not only frustrating, but physically harmful.  The lack of rest impairs attention and memory formation for TBI patients, who already have a higher rate of functional disability and higher cost of rehabilitation.  Treatments to remedy the dangerous swelling occurring after TBI exist, while underlying brain damage evident in sleep impairment as well as learning patterns remains without treatments.

The study compared mice with mild TBI to uninjured mice, and found the injured mice much less capable of staying awake for sustained periods of time.  Scientists pinned this on underactive orexin neurons, meant to maintain wakefulness, mirroring spinal fluid evidence of human TBI patients. The scientists gave the injured mice a dietary therapy of branched chain amino acids; the building blocks of neurotransmitters, chemicals released by neurons in the brain.  The results showed a restoration of normal orexin levels, and improved wakefulness.  This offers a proof-of-principle for dietary intervention as a treatment for TBI, and hopefully an avenue to help brain-injured patients regain cognitive functions.

Source:

1)     M. M. Lim, J. Elkind, G. Xiong, R. Galante, J. Zhu, L. Zhang, J. Lian, J. Rodin, N. N. Kuzma, A. I. Pack, A. S. Cohen. Dietary Therapy Mitigates Persistent Wake Deficits Caused by Mild Traumatic Brain Injury. Science Translational Medicine, 2013; 5 (215): 215ra173 DOI: 10.1126/scitranslmed.3007092

2)     Oregon Health & Science University (2013, December 11). Dietary amino acids improve sleep problems in mice with traumatic brain injury. ScienceDaily. Retrieved January 7, 2014, from http://www.sciencedaily.com­ /releases/2013/12/131211185331.htm

By: Emma Henson

  1. Controlling length of mitochondria may cure Alzheimer’s diseases Comments Off
  2. Biomarker Could Aid in Revealing Alzheimer’s Early Comments Off
  3. Michael Mullan: Brain Fitness Programs – a scam ? Comments Off
  4. Dr. Michael Mullan Article Published in Herald Tribune: Dr. Michael Mullan: Volunteer to help fight Alzheimer’s Comments Off
  5. Donation Campaign – 36 hour giving challenge campaign Comments Off
  6. Anti-Tumoral Activity of a Short Decapeptide Fragment of the Alzheimer’s Abeta Peptide. Comments Off
  7. Impaired orthotopic glioma growth and vascularization in transgenic mouse models of Alzheimer’s disease. Comments Off
  8. Characterization and use of human brain microvascular endothelial cells to examine β-amyloid exchange in the blood-brain barrier. Bachmeier C, Mullan M, Paris D. Comments Off
  9. Depletion of CXCR2 inhibits γ-secretase activity and amyloid-β production in a murine model of Alzheimer’s disease. Comments Off
  10. Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier. Comments Off
  11. Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine. Comments Off
  12. Selective dihydropyiridine compounds facilitate the clearance of β-amyloid across the blood-brain barrier. Comments Off
  13. Feasibility of Predicting MCI/AD Using Neuropsychological Tests and Serum β-Amyloid. Comments Off
  14. Flavonoids lower Alzheimer’s Aβ production via an NFκB dependent mechanism. Comments Off
  15. Roskamp Institute in Sarasota, Florida, have shown that an anatabine compound supplied by Rock Creek has beneficial effects on memory and learning in animal models of Alzheimer’s Disease. Michael Mullan, MD, Ph.D., CEO of the Roskamp Institute and his colleague, Dr. Daniel Paris, published these findings in October, 2011 in the European Journal of Pharmacology Comments Off
  16. Mike Mullan Alzheimer Researcher Comments on: Nicotine May Help Combat Memory Loss study by Dr. Newhouse Comments Off
  17. Identification of Plasma Biomarkers of TBI Outcome Using Proteomic Approaches in an APOE Mouse Model. Comments Off
  18. Anatabine lowers Alzheimer’s Aβ production in vitro and in vivo Comments Off
  19. Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer’s disease. Comments Off
  20. Genetic deletion of TNF receptor suppresses excitatory synaptic transmission via reducing AMPA receptor synaptic localization in cortical neurons. Comments Off
  21. Proteomic CNS profile of delayed cognitive impairment in mice exposed to gulf war agents. Comments Off
  22. Institute targets in on Alzheimer’s Comments Off
  23. Sarasota’s Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes Comments Off
  24. The Roskamp Institute Comments Off
  25. Roskamp Institute on Gulf War Illness Comments Off
  26. The Roskamp Institute Battles Drug Abuse Comments Off
  27. The Traumatic Brain Injury Program at the Roskamp Institute Comments Off
  28. Roskamp Institute finds one of the genetic causes for Tourettes syndrome Comments Off
  29. Sarasota’s Roskamp Institute Welcomes U.S. Senator Bill Nelson Comments Off
  30. Dr. Mullan’s Alzheimer Research Offers Invaluable Insights On The Disease Comments Off
  31. Dr. Mullan’s Alzheimer Research Identified Various Genetic Variations Comments Off
  32. Family History of Alzheimer’s disease – what does it mean? Comments Off
  33. ß-amyloid exchage in the blood-brain barrier Comments Off
  34. Why work with Alzheimer’s disease patients? Comments Off
  35. Alzheimer’s disease drug developed at Roskamp Institute approved for key clinical trial funding in Europe Comments Off
  36. Roskamp institute studies may lead to better diagnosis Comments Off
  37. Research Highlights The Direct Causes Related To The Disease Comments Off
  38. Dr. Mullan’s Alzheimer Research Involved Studying Brain Proteins Comments Off
  39. Roskamp Institute researchers show that some antibodies but, not others may be helpful in removing the Alzheimer amyloid from the brain of Alzheimer’s sufferers. Comments Off
  40. Mullan Alzheimer Research Institute Roskamp Institute aids high school students in genetic research Comments Off
  41. The Roskamp Institute investigates the role of anatabine in lowering Alzheimer’s Abeta levels. Comments Off
  42. Alzheimer Research Institute Headed By Dr. Michael Mullan Featured in the Sarasota Herald Tribune : Roskamp Institute research could help veterans Comments Off
  43. Dr. Mullan Alzheimer Presentation at Pines of Sarasota Comments Off
  44. Roskamp Institute Celebrated Veterans Day with a seminar by Alzheimer Researcher Dr. Michael Mullan Comments Off
  45. Alzheimer Expert Dr. Mullan’s comments on CD40L induces Abeta production via signaling by the granulocyte macrophage colony stimulating factor (GM-CSF) Comments Off
  46. Alzheimer Researcher Dr. Michael Mullans Note on Potent anti-angiogenic motifs within the Alzheimer beta-amyloid peptide. Comments Off
  47. Effect of NSAIDS on cognitive ability of Alzheimer’s Patient — Comment by Alzheimer Researcher Mullan Comments Off
  48. Dr. Mullan’s Alzheimer Research Notes on NSAIDS and their effect on Alzheimers disease Comments Off
  49. Roskamp Institute Gulf War Illness research program Comments Off
  50. Event: Journal Club “Disrupted-in-Schizophrenia-1 expression is regulated by β-site amyloid precursor protein cleaving enzyme-1–neuregulin cascade” Comments Off
  51. Event: Journal Club “The effect of encapsulated VEGF-secreting cells on brain amyloid load and behavioral impairment in a mouse model of Alzheimer’s disease” Comments Off
  52. News:Nomination for Business/Education Partnership Award through the School District of Manatee County’s ePIE program Comments Off
  53. News:Roskamp Institute was recognized by the South East High School Technical Student association for partnering will the in a diabetes project Comments Off
  54. News: FDA advisory committee unanimously recommends approval of Novartis investigational treatment FTY720 to treat relapsing remitting MS Comments Off
  55. Event: Journal Club “NF-jB activity affects learning in aversive tasks: Possible actions via modulation of the stress axis” Comments Off
  56. News Comments Off
  57. APOLIPOPROTEIN E GENOTYPE AND OXIDATIVE STRESS RESPONSE TO TRAUMATIC BRAIN INJURY Comments Off
  58. Event Journal Club:Amyloid-β and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer’s disease mice Comments Off
  59. Event: Journal Club Comments Off
  60. Announcement Comments Off
  61. News:Dr Crawford will be speaking at 2nd Annual Girls S.T.E.M. Summit Comments Off
  62. Alzheimer’s beta-amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFR-2 Comments Off
  63. Tech Tips, #2: Making a homemade frit for fused silica columns Comments Off
  64. Do You Or Someone You Care For Suffer From Alzheimer’s Disease? Comments Off
  65. Reduction of b-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer’s disease Comments Off
  66. NEWS RELEASE:Investigational Immune Intervention Slows Brain Atrophy in Alzheimer’s Patients Comments Off
  67. Journal Club Comments Off
  68. FREE MEMORY SCREENING-Sarasota FL Comments Off
  69. Anti-Tumoral Activity of a Short Decapeptide Fragment of the Alzheimer’s Abeta Peptide Comments Off
  70. Diagnostic utility of APOE, soluble CD40, CD40L, and Abeta1-40 levels in plasma in Alzheimer’s disease Comments Off
  71. CD40/CD40L interaction induces Abeta production and increases gamma-secretase activity independently of tumor necrosis factor receptor associated factor (TRAF) signaling. Comments Off
  72. Roskamp Institute Poster Abstract from VA Reasearch Week Comments Off
  73. Handling Unstructured Data in Biological Research and Clinical Trials Comments Off
  74. Tech Tips: Comments Off
  75. Roskamp Institute is participating in VA Research Week Activities Comments Off
  76. Roskamp Institute-LECOM collaboration Comments Off
  77. High serum Abeta and vascular risk factors in first-degree relatives of Alzheimer’s disease patients Comments Off
  78. Journal Club: The presence of sodium dodecyl sulphate-stable Aβ dimers is strongly associated with Alzheimer-type dementia Comments Off
  79. Alzheimer’s Disease Anti-Inflammatory Prevention Trial Comments Off
  80. Roskamp Institute is at Facebook! Comments Off
  81. Adaptation of the circular platform spatial memory task for mice: use in detecting cognitive impairment in the APPSW transgenic mouse model for Alzheimer’s disease Comments Off
  82. Characteristics of thein VitroVasoactivity of β-Amyloid Peptides Comments Off
  83. Reduction of β-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer’s disease Comments Off
  84. Cross Validation of the Montreal Cognitive Assessment in Community Dwelling Older Adults Residing in the Southeastern US Comments Off
  85. Volunteers for early detection of cognitive decline in older adults Comments Off
  86. Roskamp Institute hosted a town hall meeting for the Alzheimer’s Association. Comments Off
  87. Roskamp Institute Scientist Awarded a grant from the Alzheimers Association to investigate a novel therapeutic agent for the treatment of Alzheimer’s Disease. Comments Off
  88. Roskamp Institute Identifies New Class of Drugs to Treat Alzheimer’s Disease. Comments Off
  89. Roskamp Institute Announces Enrollment of First Students to Participate in its Innovative Research Doctorate Program Comments Off
  90. Southeast High School’s Roskamp Institute project placed first in Florida and fifth in National Technology Students Association finals Comments Off
  91. Local Researchers at Roskamp Institute to Test Investigational Gammaglobulin Treatment for Alzheimer’s Disease Comments Off
  92. World Alzheimer’s Day: Leaders Call for Early Diagnosis and Aggressive Research Comments Off
  93. Dementia in Older Women Comments Off
  94. Alzheimer’s and Blood Pressure Comments Off
  95. What do the names of Barack Obama, Hillary Clinton, and John McCain have to do with Alzheimer’s disease? Comments Off
  96. Double Amyloid Causes Memory Loss Comments Off
  97. First Critical Clinical Tests of the Amyloid Theory of Alzheimer’s Disease Comments Off
  98. Elan Vaccine and Alzheimer’s Disease Drug development Comments Off
  99. Alzheimer’s Disease Drug development Comments Off
  100. Clinical research for Alzheimer’s Disease at the Roskamp Institute Comments Off
  101. DRUG ADDICTION RESEARCH AT THE ROSKAMP INSTITUTE Comments Off
  102. Traumatic Brain Injury in the War Zone Comments Off
  103. Research On Traumatic Brain Injury At The Roskamp Institute Comments Off
  104. ABeta as Antiangiogenic drug Comments Off
  105. Roskamp Institute examines the cellular responses to biological warfare agents Comments Off
  106. Clinical Trials for Alzheimer’s Disease at the Roskamp Institute Comments Off
  107. Press release for James & Esther King Biomedical Research Program grant Comments Off
  108. Genetic manipulation of CD40L reduces Tau phosphorylation Comments Off
  109. The granulocyte macrophage-colony stimulating factor (GM-CSF) regulates amyloid production Comments Off
  110. Potent antiangiogenic motif in amyloid beta Comments Off
  111. CD40L induces Abeta production via signaling by the granulocyte macrophage colony stimulating factor (GM-CSF) Comments Off
  112. Potent anti-angiogenic motifs within the Alzheimer beta-amyloid peptide Comments Off
  113. Effect of NSAIDS on cognitive ability of Alzheimer’s Patients Comments Off
  114. NSAIDS and their effect on Alzheimers disease Comments Off
  115. Roskamp Institute is Part of a Great Technology Cluster Comments Off
  116. Roskamp Institute Receives Lung Cancer Research Grant Comments Off
  117. Roskamp Institute Recognized for Its Beautification Efforts Comments Off
  118. Roskamp Institute Helps Florida’s Economy Comments Off
  119. Roskamp Institute Supports Moves for Greater State Funding of Biotech Research Comments Off
  120. Roskamp Institute Looking for Alzheimer’s Clinical Trial Participants Comments Off
  121. The Roskamp Institute Plans Alzheimer’s Treatment Trial Comments Off
  122. Roskamp’s Fiona Crawford to Participate in Panel Discussion Comments Off
  123. Roskamp Institute Will Host Neuroscience Doctorate Research Program Comments Off
  124. Roskamp Institute Alzheimer’s Research Validated by Independent Japanese Study Comments Off
  125. Roskamp Institute Receives Award of Appreciation Comments Off
  126. Roskamp Institute Studying Potential Usefulness of Beta-amyloid in Treating Alzheimer’s Comments Off
  127. Nilvadipine an anti-hypertensive drug, as a potential treatment for Alzheimer’s disease Comments Off
  128. Anti-hypertension Drugs and Alzheimers Comments Off
  129. Roskamp Institute’s Fiona Crawford to Moderate at Power of Women Series Comments Off
  130. Conscientious people are less prone to Alzheimer’s Comments Off
  131. The Traumatic Brain Injury Program at the Roskamp Institute Comments Off
  132. Sarasota’s Roskamp Institute Welcomes U.S. Senator Bill Nelson Comments Off
  133. Senator Nelson Visit Roskamp Institute Comments Off
  134. Roskamp Institute Aims to Help Injured Soldiers Comments Off
  135. British Experts Question Need for Baby Scans Comments Off
  136. Chromosomes Shed New Light on Down Syndrome Comments Off
  137. Down Syndrome Patient Learning New Skills Comments Off
  138. Novartis Required to Correct Advertising Comments Off
  139. Tracking Wandering Alzheimer’s Sufferers Comments Off
  140. Alzheimer’s Caregiver Training Comments Off
  141. Attending College with Intellectual Disabilities Comments Off
  142. National Down Syndrome Society Comments Off
  143. Alzheimer’s Widow to Serve as British Government Adviser Comments Off
  144. Alzheimer’s Disease Disscusion Forum Comments Off
  145. The Roskamp Institute Is Good for Manatee County, Florida Comments Off
  146. Roskamp Institute Obesity and Diabetes Study Official Release Comments Off
  147. Roskamp Institute Study Examines Obesity Comments Off
  148. Clinical Trial Information Comments Off
  149. Sarkozy Vows to Defeat Alzheimer’s Comments Off
  150. Study: Spice can help Alzheimer’s Patients Comments Off
  151. Want a job in science research? Comments Off
  152. Roskamp Institute Tries to Improve Life of Alzheimer’s Suffers Comments Off
  153. Neuropsychology Comments Off
  154. Study: Alzheimer’s Cases May Quadruple by 2050 Comments Off
  155. Alzheimer’s Support Groups Comments Off
  156. Roskamp Celebrated 2006 World Alzheimer’s Day with Clinical Trial Lauch Comments Off
  157. Good News for Alzheimer’s Drug Comments Off
  158. Roskamp Institute Announces New Treatment Comments Off
  159. Roskamp Institute Media Coverage Comments Off
  160. The Roskamp Institute is Participating in a New Phase III MS Study Comments Off
  161. Michael Mullan Featured in Another Story Comments Off
  162. Roskamp’s Michael Mullan Interviewed by St. Petersburg Times Comments Off
  163. Sarasota’s Roskamp Institute Announces Participation in Multiple Sclerosis Study Comments Off
  164. Roskamp Institute recruiting for clinical trials Comments Off
  165. Roskamp Institute Announces New Class Of Drugs That Can Impact Alzheimer’s Disease Comments Off